Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

被引:46
作者
Amato, Robert J. [1 ]
Shingler, William [2 ]
Naylor, Stuart [2 ]
Jac, Jaroslaw [1 ]
Willis, James [1 ]
Saxena, Somyata [1 ]
Hernandez-McClain, Joan [1 ]
Harrop, Richard [2 ]
机构
[1] Methodist Hosp, Res Inst, Houston, TX 77030 USA
[2] Oxford BioMed UK Ltd, Medawar Ctr, Oxford, England
关键词
D O I
10.1158/1078-0432.CCR-08-0668
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The attenuated vaccinia virus modified vaccinia ankara (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). TroVax has been evaluated in an open-label phase II trial in metastatic renal cell cancer patients in which the vaccine was administered in combination with interleukin-2 (IL-2). The safety, immunologic, and clinical efficacy of TroVax in combination with IL-2 was determined. Experimental Design: Twenty-five patients with metastatic renal cell cancer were treated with TroVax plus IL-2. 5T4-specific cellular and humoral responses were monitored throughout the study. Clinical responses were assessed by measuring changes in tumor burden by computed tomography or magnetic resonance imaging scan. Results: TroVax was well tolerated with no serious adverse event attributed to vaccination. Of 25 intention-to-treat patients, 21 mounted 5T4-specific antibody responses. Two patients showed a complete response for > 24 months and one a partial response for > 12 months. Six patients had disease stabilization from 6 to > 21 months. Median progression-free survival (PFS) and overall survival (OS) were > 3.37 months (range, 1.50-> 24.76) and > 12.87 months (range, 1.90-> 24.76), respectively. A statistically significant relationship was detected between the magnitude of 5T4-specific antibody responses and PFS and OS. Conclusion: TroVax in combination with IL-2 was safe and well tolerated in all patients. The high frequency of 5T4-specific immune responses and good clinical response rate are encouraging and warrant further investigation.
引用
收藏
页码:7504 / 7510
页数:7
相关论文
共 17 条
[1]   Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia [J].
Barrow, KM ;
Ward, CM ;
Rutter, J ;
Ali, S ;
Stern, PL .
DEVELOPMENTAL DYNAMICS, 2005, 233 (04) :1535-1545
[2]   Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy [J].
Cangiano, T ;
Liao, J ;
Naitoh, J ;
Dorey, F ;
Figlin, R ;
Belldegrun, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :523-528
[3]  
Carsberg CJ, 1996, INT J CANCER, V68, P84, DOI 10.1002/(SICI)1097-0215(19960927)68:1<84::AID-IJC15>3.3.CO
[4]  
2-P
[5]   Epithelial-mesenchymal transition events during human embryonic stem cell differentiation [J].
Eastham, Angela M. ;
Spencer, Helen ;
Soncin, Francesca ;
Ritson, Sarah ;
Merry, Catherine L. R. ;
Stern, Peter L. ;
Ward, Christopher M. .
CANCER RESEARCH, 2007, 67 (23) :11254-11262
[6]   Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy [J].
Griffiths, RW ;
Gilham, DE ;
Dangoor, A ;
Ramani, V ;
Clarke, NW ;
Stern, PL ;
Hawkins, RE .
BRITISH JOURNAL OF CANCER, 2005, 93 (06) :670-677
[7]   Treatment of patients with metastatic renal cell cancer - A RAND appropriateness panel [J].
Halbert, Ronald J. ;
Figlin, Robert A. ;
Atkins, Michael B. ;
Bernal, Myriam ;
Hutson, Thomas E. ;
Uzzo, Robert G. ;
Bukowski, Ronald M. ;
Khan, Khuda Dad ;
Wood, Christopher G. ;
Dubois, Robert W. .
CANCER, 2006, 107 (10) :2375-2383
[8]   Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated [J].
Harrop, R ;
Ryan, MG ;
Myers, KA ;
Redchenko, I ;
Kingsman, SM ;
Carroll, MW .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (09) :1081-1090
[9]   Viral vectors for cancer immunotherapy [J].
Harrop, R ;
Carroll, MW .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :804-817
[10]   Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses [J].
Harrop, Richard ;
Drury, Noel ;
Shingler, William ;
Chikoti, Priscilla ;
Redchenko, Irina ;
Carroll, Miles W. ;
Kingsman, Susan M. ;
Naylor, Stuart ;
Melcher, Alan ;
Nicholls, Joanna ;
Wassan, Harpreet ;
Habib, Nagy ;
Anthoney, Alan .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4487-4494